The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
Received Date : 04 Dec 2017
Accepted Date : 15 Mar 2018
Doi: 10.1016/j.jons.2018.03.001 - Article's Language: EN
Journal of Oncological Sciences 4 (2018) 60-61
This is an open access article under the CC BY-NC-ND license
Introduction: The use of FOLFOXIRI (oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil) as first-line therapy for metastatic colorectal cancer (mCRC) is well-established. However, there is no data about the effectiveness of this regimen in pretreated patients in the current literature. In this case report, we aim to evaluate the efficacy and benefit of FOLFOXIRI in patients who received standard regimens. Case report: 3 patients were treated with FOLFOXIRI and 1 patient received FOLFOXIRI þ bevasizumab.Three patients had a partial response to FOLFOXIRI; one of these patients showed disease progression on this chemotherapy regimen and died. Progression free survival (PFS) of three patients was 5.5, 9 and 7.5 months respectively. One patient showed progression without any response to treatment. Conclusion: We observed a partial response in 3 patients who were treated with FOLFOXIRI and their progression-free survival was more than 3 months. These patients were treated with FOLFOXIRI as a third or fourth line therapy. FOLFOXIRI should be considered as an alternative option in patients who have received standard treatments with good performance status.